Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Pascal Turlure et al.|The Lancet|2012Cited by 994
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaÉric Jourdan, Hervé Dombret, Nicolas Boissel et al.|Blood|2013Cited by 357
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With<i>NPM1</i>Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Nicolas Boissel, Aline Renneville et al.|Journal of Clinical Oncology|2017Cited by 292